CLINICAL_TRIALS
trial_result
· 2021-11-17
Clinical Trial Update: Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome [Phase 3]
Summary
Phase 3 study of intranasal carbetocin (LV-101) in Prader-Willi syndrome completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Levo Therapeutics, Inc. | Conditions: Prader-Willi Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2021-11-17